Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3090) 3090
Newsletter (57) 57
Magazine Article (27) 27
Newspaper Article (15) 15
Book Chapter (12) 12
Dissertation (10) 10
Book Review (6) 6
Book / eBook (2) 2
Conference Proceeding (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2119) 2119
albuterol - analogs & derivatives (1906) 1906
salmeterol xinafoate (1753) 1753
science & technology (1676) 1676
life sciences & biomedicine (1642) 1642
salmeterol (1452) 1452
male (1215) 1215
female (1150) 1150
asthma - drug therapy (1146) 1146
albuterol - therapeutic use (1018) 1018
asthma (969) 969
respiratory system (966) 966
administration, inhalation (852) 852
albuterol - administration & dosage (849) 849
fluticasone (847) 847
middle aged (843) 843
adult (840) 840
biological and medical sciences (780) 780
medical sciences (773) 773
bronchodilator agents - therapeutic use (742) 742
bronchodilator agents - administration & dosage (636) 636
aged (596) 596
double-blind method (580) 580
drug therapy, combination (546) 546
pharmacology. drug treatments (519) 519
treatment outcome (518) 518
pulmonary disease, chronic obstructive - drug therapy (516) 516
abridged index medicus (450) 450
adrenergic beta-agonists - therapeutic use (450) 450
androstadienes - administration & dosage (449) 449
general & internal medicine (443) 443
adolescent (442) 442
drug combinations (439) 439
androstadienes - therapeutic use (415) 415
drug therapy (412) 412
albuterol - pharmacology (395) 395
pharmacology & pharmacy (381) 381
albuterol - adverse effects (353) 353
formoterol fumarate (352) 352
asthma - physiopathology (340) 340
adrenergic beta-agonists - administration & dosage (334) 334
chronic obstructive pulmonary disease (326) 326
child (303) 303
pneumology (286) 286
formoterol (285) 285
fluticasone-salmeterol drug combination (271) 271
medicine, general & internal (267) 267
bronchodilator agents - adverse effects (258) 258
chronic obstructive pulmonary disease, asthma (257) 257
cross-over studies (252) 252
forced expiratory volume - drug effects (250) 250
adrenergic beta-agonists - pharmacology (245) 245
lung diseases, obstructive (244) 244
allergy (243) 243
time factors (232) 232
dose-response relationship, drug (224) 224
animals (218) 218
anti-asthmatic agents - therapeutic use (215) 215
fluticasone propionate (215) 215
respiratory tract diseases (215) 215
anti-asthmatic agents - administration & dosage (212) 212
corticosteroids (209) 209
copd (206) 206
research (200) 200
forced expiratory volume (195) 195
pulmonary disease, chronic obstructive - physiopathology (194) 194
immunology (193) 193
adrenal cortex hormones - administration & dosage (190) 190
adrenergic beta-agonists - adverse effects (189) 189
bronchodilator agents - pharmacology (188) 188
quality of life (184) 184
respiratory function tests (183) 183
dosage and administration (179) 179
ethanolamines - administration & dosage (177) 177
ethanolamines - therapeutic use (175) 175
care and treatment (169) 169
critical care medicine (168) 168
randomized controlled trials as topic (165) 165
tiotropium bromide (165) 165
nebulizers and vaporizers (163) 163
drug administration schedule (162) 162
analysis (151) 151
adrenal cortex hormones - therapeutic use (149) 149
pulmonary and respiratory medicine (148) 148
androstadienes - adverse effects (144) 144
severity of illness index (133) 133
aged, 80 and over (131) 131
glucocorticoids - therapeutic use (129) 129
antiasthmatic agents (125) 125
scopolamine derivatives - therapeutic use (124) 124
clinical trials (123) 123
health aspects (123) 123
salbutamol (122) 122
cardiac & cardiovascular systems (121) 121
cardiovascular system & cardiology (121) 121
adrenergic beta-2 receptor agonists - administration & dosage (118) 118
pulmonary/respiratory (118) 118
tiotropium (118) 118
studies (117) 117
glucocorticoids - administration & dosage (113) 113
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3007) 3007
German (81) 81
French (41) 41
Japanese (32) 32
Polish (25) 25
Chinese (24) 24
Spanish (21) 21
Italian (15) 15
Danish (10) 10
Portuguese (7) 7
Russian (5) 5
Romanian (4) 4
Dutch (3) 3
Czech (2) 2
Hungarian (2) 2
Korean (2) 2
Norwegian (2) 2
Swedish (2) 2
Breton (1) 1
Hebrew (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text ANÁLISIS DE COSTO EFECTIVIDAD DEL USO DE BUDESONIDA/FORMOTEROL FRENTE A SALMETEROL/FLUTICASONA, EN PACIENTES CON ASMA MODERADA Y SEVERA EN COLOMBIA
by ME Romero Prada and NC Roa Cardenas and LM Huerfano
Value in health, ISSN 1098-3015, 10/2017, Volume 20, Issue 9, p. A889
Salmeterol | Formoterol
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
by Wedzicha, Jadwiga A and Banerji, Donald and Chapman, Kenneth R and Vestbo, Jørgen and Roche, Nicolas and Ayers, R. Timothy and Thach, Chau and Fogel, Robert and Patalano, Francesco and Vogelmeier, Claus F and FLAME Investigators
The New England journal of medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 23, pp. 2222 - 2234
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Glycopyrrolate - adverse effects | Indans - adverse effects | Pulmonary Disease, Chronic Obstructive - mortality | Glucocorticoids - therapeutic use | Double-Blind Method | Glycopyrrolate - therapeutic use | Humans | Middle Aged | Administration, Inhalation | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Fluticasone-Salmeterol Drug Combination - adverse effects | Quinolones - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Indacaterol | Dosage and administration | Salmeterol | Respiratory therapy | Acetylcholine receptors (muscarinic) | Glucocorticoids | Lung diseases | Fluticasone | Preventive medicine | Patients | Inhalation | Obstructive lung disease | Comparative studies | Chronic obstructive pulmonary disease | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text IMPROVEMENT IN SGRQ COMPONENT SCORE WITH INDACATEROL/ GLYCOPYRRONIUM VERSUS SALMETEROL/FLUTICASONE: RESULTS FROM THE FLAME STUDY
Respirology (Carlton, Vic.), ISSN 1323-7799, 11/2017, Volume 22, Issue S3, pp. 176 - 177
Salmeterol | Fluticasone
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text INDACATEROL/GLYCOPYRRONIUM (IND/GLY) REDUCES THE RISK OF CLINICALLY IMPORTANT DETERIORATION (CID) VERSUS SALMETEROL/FLUTICASONE (SFC): THE FLAME STUDY
Respirology (Carlton, Vic.), ISSN 1323-7799, 11/2017, Volume 22, Issue S3, pp. 178 - 178
Salmeterol | Fluticasone
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Utility of Von Pechman synthesis of coumarin reaction for development of spectrofluorimetric method for quantitation of salmeterol xinafoate in pharmaceutical preparations and human plasma
by Awad, Mohamed and Hammad, Mohamed A and Abdel‐Megied, Ahmed M and Omar, Mahmoud A
Luminescence (Chichester, England), ISSN 1522-7235, 08/2018, Volume 33, Issue 5, pp. 913 - 918
coumarin derivatives | spectrofluorimetry, salmeterol xinafoate | human plasma | pharmaceutical analysis | Life Sciences & Biomedicine | Biochemistry & Molecular Biology | Science & Technology | Fluorescent Dyes - chemical synthesis | Fluorescent Dyes - chemistry | Spectrometry, Fluorescence - methods | Limit of Detection | Reproducibility of Results | Temperature | Solvents - chemistry | Humans | Coumarins - chemistry | Sulfuric Acids - chemistry | Salmeterol Xinafoate - analysis | Time Factors | Salmeterol Xinafoate - blood | Salmeterol Xinafoate - chemistry | Pharmaceutical Preparations | Acetoacetates - chemistry | Analysis | Methods | Salmeterol | Drugs | Correlation coefficient | Analytical methods | Regulatory agencies | Methodology | Correlation coefficients | Fluorescence | Firmness | Quantitation | Phenolic compounds | Coumarin | Recovery | Blood plasma | Salmeterol xinafoate | Mathematical analysis | Phenols | Detection | Chemical synthesis | Pharmaceuticals | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI)
by Rowland, Martin and Rowland, Martin and Cavecchi, Alessandro and Cavecchi, Alessandro and Thielmann, Frank and Thielmann, Frank and Kulon, Janusz and Kulon, Janusz and Shur, Jag and Shur, Jag and Price, Robert and Price, Robert
Pharmaceutical research, ISSN 0724-8741, 1/2019, Volume 36, Issue 1, pp. 1 - 14
Biochemistry, general | bipolar next generation impactor | pressurized metered dose inhaler | Biomedicine | Pharmacy | Bipolar charge | Medical Law | electrostatic charge | Pharmacology/Toxicology | Biomedical Engineering and Bioengineering | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Suspensions - chemistry | Fluticasone - chemistry | Fluticasone-Salmeterol Drug Combination - chemistry | Administration, Inhalation | Aerosols - chemistry | Static Electricity | Equipment Design | Technology, Pharmaceutical - instrumentation | Chemistry, Pharmaceutical - instrumentation | Particle Size | Powders - chemistry | Salmeterol Xinafoate - chemistry | Surface Properties | Metered Dose Inhalers | Measurement | Bipolar disorder | Fluticasone | Clouds | Salmeterol | Resveratrol | Propionic acid | Crystals | Particulates | Ice | Charge distribution | Electrostatic precipitators | Ice formation | Salmeterol xinafoate | Ice crystals | Ratios | Aerosols | Precipitators | Inhalers | Charged particles | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma
by Stempel, David A and Szefler, Stanley J and Pedersen, Søren and Zeiger, Robert S and Yeakey, Anne M and Lee, Laurie A and Liu, Andrew H and Mitchell, Herman and Kral, Kenneth M and Raphiou, Ibrahim H and Prillaman, Barbara A and Buaron, Kathleen S and Yun Kirby, Suyong and Pascoe, Steven J and VESTRI Investigators
The New England journal of medicine, ISSN 0028-4793, 09/2016, Volume 375, Issue 9, pp. 840 - 849
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Bronchodilator Agents - administration & dosage | Double-Blind Method | Humans | Proportional Hazards Models | Administration, Inhalation | Child, Preschool | Male | Asthma - drug therapy | Fluticasone-Salmeterol Drug Combination - administration & dosage | Fluticasone-Salmeterol Drug Combination - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Fluticasone - administration & dosage | Adrenergic beta-1 Receptor Agonists - administration & dosage | Metered Dose Inhalers | Adrenergic beta-2 Receptor Agonists - administration & dosage | Female | Adrenergic beta-1 Receptor Agonists - adverse effects | Bronchodilator Agents - adverse effects | Child | Delayed-Action Preparations | Fluticasone - adverse effects | Usage | Children | Steroids (Drugs) | Health aspects | Risk factors | Asthma | Respiratory therapy | Pediatrics | Glucocorticoids | Propionic acid | Salmeterol | Fluticasone | Patients | Children & youth | Meta-analysis | Patient safety | Intubation | Safety | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery
by Liu, Sha and Watts, Alan B and Du, Ju and Bui, Amanda and Hengsawas, Soraya and Peters, Jay I and Williams, Robert O
European journal of pharmaceutics and biopharmaceutics, ISSN 0939-6411, 10/2015, Volume 96, pp. 132 - 142
Salmeterol xinafoate | Fixed dose combination | Mometasone furoate | Brittle matrix powder | Thin-film freezing | Co-deposition | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Mometasone Furoate - administration & dosage | Administration, Inhalation | Salmeterol Xinafoate - pharmacokinetics | Male | Salmeterol Xinafoate - administration & dosage | Rats, Sprague-Dawley | Chemistry, Pharmaceutical | Drug Delivery Systems | Particle Size | Tissue Distribution | Animals | Excipients - chemistry | Microscopy, Electrochemical, Scanning | X-Ray Diffraction | Salmeterol Xinafoate - chemistry | Surface Properties | Drug Compounding | Calorimetry, Differential Scanning | Female | Lung - metabolism | Bronchoalveolar Lavage Fluid - chemistry | Mometasone Furoate - chemistry | Mometasone Furoate - pharmacokinetics | Drug Combinations | Drugs | Drug delivery systems | Mometasone | Salmeterol | Vehicles | Steroids | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD
by Contoli, Marco and Pauletti, Alessia and Rossi, Maria Rita and Spanevello, Antonio and Casolari, Paolo and Marcellini, Andrea and Forini, Giacomo and Gnesini, Giulia and Marku, Brunilda and Barnes, Neil and Rizzi, Andrea and Curradi, Giacomo and Caramori, Gaetano and Morelli, Paolo and Papi, Alberto
The European respiratory journal, ISSN 0903-1936, 10/2017, Volume 50, Issue 4, pp. 1700451 - 1700451
Life Sciences & Biomedicine | Respiratory System | Science & Technology | Sputum - microbiology | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Pulmonary Disease, Chronic Obstructive - microbiology | Humans | Middle Aged | Male | Drug Monitoring - methods | Salmeterol Xinafoate - adverse effects | Bacterial Load - drug effects | Forced Expiratory Volume | Respiratory Tract Infections - microbiology | Long Term Adverse Effects - microbiology | Pulmonary Disease, Chronic Obstructive - blood | Bacterial Load - methods | Female | Eosinophils - pathology | Bronchodilator Agents - adverse effects | Fluticasone - adverse effects | Glucocorticoids - adverse effects | Pulmonary Disease, Chronic Obstructive - diagnosis | Administration, Inhalation | Treatment Outcome | Salmeterol Xinafoate - administration & dosage | Respiratory Tract Infections - diagnosis | Long Term Adverse Effects - diagnosis | Fluticasone - administration & dosage | Respiratory Function Tests | Viral Load - drug effects | Viral Load - methods | Pulmonary Disease, Chronic Obstructive - drug therapy | Respiratory therapy | Corticoids | Leukocytes (eosinophilic) | Propionic acid | Salmeterol | Microbiomes | Inflammation | Fluticasone | Inhalation | Respiratory tract | Sputum | Bacteria | Chronic obstructive pulmonary disease | Long-term effects
Journal Article
Details down arrow
10. Full Text Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers
by Soulele, Konstantina and Macheras, Panos and Karalis, Vangelis
Biopharmaceutics & drug disposition, ISSN 0142-2782, 10/2017, Volume 38, Issue 7, pp. 407 - 419
parallel absorption | salmeterol xinafoate | dry powder inhalers | population pharmacokinetics | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Adrenergic beta-2 Receptor Agonists - pharmacokinetics | Bronchodilator Agents - blood | Asthma - metabolism | Dry Powder Inhalers | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Administration, Inhalation | Salmeterol Xinafoate - pharmacokinetics | Male | Salmeterol Xinafoate - administration & dosage | Cross-Over Studies | Young Adult | Adrenergic beta-2 Receptor Agonists - blood | Salmeterol Xinafoate - blood | Bronchodilator Agents - pharmacokinetics | Adrenergic beta-2 Receptor Agonists - administration & dosage | Adult | Female | Therapeutic Equivalency | Powders | Inhalers | Analysis | Asthma | Body weight | Salmeterol | Data processing | Population studies | Pharmacology | Patients | Powder | Absorption | Lungs | Activated carbon | Pharmacokinetics | Activated charcoal | Charcoal | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
by Magnussen, Helgo and Disse, Bernd and Rodriguez-Roisin, Roberto and Kirsten, Anne and Watz, Henrik and Tetzlaff, Kay and Towse, Lesley and Finnigan, Helen and Dahl, Ronald and Decramer, Marc and Chanez, Pascal and Wouters, Emiel F.M and Calverley, Peter M.A and WISDOM Investigators
The New England journal of medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 14, pp. 1285 - 1294
ISOLDE | OBSTRUCTIVE PULMONARY-DISEASE | FLUTICASONE PROPIONATE | PREVENTION | TIOTROPIUM | RANDOMIZED CONTROLLED-TRIAL | CORTICOSTEROIDS | SALMETEROL | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Chronic obstructive pulmonary disease, asthma | Pneumology | Spirometry | Glucocorticoids - administration & dosage | Salmeterol Xinafoate | Bronchodilator Agents - administration & dosage | Double-Blind Method | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Proportional Hazards Models | Administration, Inhalation | Albuterol - analogs & derivatives | Male | Fluticasone | Withholding Treatment | Androstadienes - administration & dosage | Albuterol - administration & dosage | Scopolamine Derivatives - administration & dosage | Female | Aged | Drug Therapy, Combination | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide | Lung diseases, Obstructive | Care and treatment | Corticosteroids | Research | Patient outcomes | Respiratory therapy | Respiratory function | Glucocorticoids | Medical treatment | Propionic acid | Lung diseases | Salmeterol | Patients | Dyspnea | Obstructive lung disease | Bronchodilators | Chronic obstructive pulmonary disease | Respiration | Index Medicus | Abridged Index Medicus | Case studies | Estudi de casos | Malalties pulmonars obstructives cròniques | Corticosteroides | Chronic obstructive pulmonary diseases | Adrenocortical hormones
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights